SRIMATHI R

Dr. SRIMATHI R

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
ASAnjana Vidya Srivathsa
Anjana Vidya Srivathsa
NSNandini Markuli Sadashivappa
Nandini Markuli Sadashivappa
AHApeksha Krishnamurthy Hegde
Apeksha Krishnamurthy Hegde
SRSRIMATHI R
SRIMATHI R
AMAgasa Ramu Mahesh
Agasa Ramu Mahesh
PPParasuraman Pavadai
Parasuraman Pavadai
Artificial intelligence (AI) speeds up the drug development process and reduces its time, as well as the cost which is of enormous importance in outbreaks such as COVID-19. It uses a set of machine learning algorithms that collects the available data from resources, categorises, processes and develops novel learning methodologies. Virtual screening is a successful application of AI, which is used in screening huge drug-like databases and filtering to a small number of compounds. The brain’s thinking of AI is its neural networking which uses techniques such as Convoluted Neural Network (CNN), Recursive Neural Network (RNN) or Generative Adversial Neural Network (GANN). The application ranges from small molecule drug discovery to the development of vaccines. In the present review article, we discussed various techniques of drug design, structure and ligand-based, pharmacokinetics and toxicity prediction using AI. The rapid phase of discovery is the need of the hour and AI is a targeted approach to achieve this.

1 April 2020 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
SRSRIMATHI R
SRIMATHI R
GJGurunathan Jayaraman
Gurunathan Jayaraman

28 August 2024 in Natural Resources for Human Health
Verified
Journal Article
Open access
SKSujatha Kuppuswamy
Sujatha Kuppuswamy
JAJerad Suresh Ayyadurai
Jerad Suresh Ayyadurai
SRSRIMATHI R
SRIMATHI R
Quercetin, a secondary metabolite and bioflavonoid, has been explored in recent times for its anti-diabetic potential owing to its wide pharmacological benefits, including antioxidant, anti-inflammatory, anti-allergic, cardiovascular protection, anti-lipidemic, and anti-arthritic properties. The presence of five hydroxyl groups contribute to its therapeutic properties by lowering blood glucose levels, increasing insulin production, improving pancreatic beta cells, and increasing glucose tolerance. Due to its antidiabetic efficacy in clinical studies, similar to other marketed drugs, studies have been conducted on the co-administration of quercetin with metformin, liraglutide, and resveratrol producing marked changes in serum glucose levels synergistically. Furthermore, they have the potential to combat adverse effects such as hypoglycaemia and hypolipidemia caused by other antidiabetic drugs. The mechanistic pathway by which quercetin causes reduced glucose levels is not clearly understood and, in this review, we discuss in detail the predictive pathways by which quercetin executes its anti-oxidant and anti-diabetic efficacy.

6 October 2026 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SDSathish Kumar J. D.
Sathish Kumar J. D.
SKSujatha Kuppuswamy
Sujatha Kuppuswamy
KVKeerthana J. V.
Keerthana J. V.
HBHarish Karthik B.
Harish Karthik B.
SRSRIMATHI R
SRIMATHI R
Cancer is the leading cause of mortality worldwide. It encompasses a spectrum of malignancies that include lung, stomach, colon, prostate, liver, and skin cancers depending on the organ it affects. Epidemiological evidence indicates that regular consumption of cruciferous vegetables leads to a 10–20% reduction in the risk of lung, breast, and colorectal cancers and bioactive dietary constituents. The lipophilic character of phytochemicals facilitates membrane permeability and selective target engagement, underscoring their pharmacological relevance. Daily dietary intake introduces varying amounts of bioactive constituents that can act as preventive agents, thereby improving human health. In this review, we discuss the therapeutic potential of selected dietary natural products, focusing on cinnamaldehyde, eugenol, β-glucan, gingerol, shogaol, curcumin, and epigallocatechin gallate (EGCG). Strong scientific literature studies support the role of these compounds in targeting key molecular pathways, including the PI3K/AKT/mTOR pathway, caspase-3 activation, and Signal Transducer and Activator of Transcription (STAT) signaling. Bioavailability, dosing, and safety profiles remain challenges, particularly in ensuring that these factors do not hinder therapeutic efficacy. Analyzing the pharmacophoric features and discussing their potential for structural optimization leads to the development of clinical candidates in the market. Combination therapy of plant-derived bioactive compounds with anticancer drugs has improved patient outcomes in many studies, leading to the development of natural product-assisted therapeutics in the future.

16 March 2026 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
GVG Vivekananthan
G Vivekananthan
VSVarun Sankar Siva Subramaniam
Varun Sankar Siva Subramaniam
NSNj Sai Sruthi
Nj Sai Sruthi
MJM Jayashree
M Jayashree
BDBasavana Gowda Hosur Dinesh
Basavana Gowda Hosur Dinesh
SRSRIMATHI R
SRIMATHI R
Introduction:: Dual inhibitors of AROM and STS (DASIs), through their synergistic action, hold the potential to suppress estrogen biosynthesis at multiple points. It also overcomes limitations associated with single-enzyme inhibition and reduces the risk of resistance development. In order to potentially improve the clinical outcomes in hormone-dependent breast cancers, 1,2,4-triazole derivatives having similar structural characteristics to third-generation Aromatase Inhibitors (AIs), including exemestane, letrozole, and anastrozole, were subjected to ligand-based screening. This research study comparatively analyzes the drug candidates as DASIs that aim at the development of advanced therapeutic strategies for breast cancer treatment. Materials and Methods:: In this study, a set of 172 biphenyl 1,2,4-triazole derivatives with defined biological activity against AROM and STS enzymes was subjected to 3DQSAR modelling, followed by ADMET, molecular docking, and dynamics. results: Through 3D-QSAR significant statistical parameters of aromatase (q² = 0.8429, r² = 0.8874, r²pred = 0.8252) and steroidal sulfatase (q² = 0.8877, r² = 0.9402, r²pred = 0.9376) indicated the accuracy and reliability and its good prediction power of the model. The external validation set further claimed its capability in external predictions. Furthermore, molecular docking was found to be -9.94 for aromatase and -9.41 for STS, along with molecular dynamics at a time period of 100 ns elucidated the stability of the docked complexes. Results:: Through 3D-QSAR, significant statistical parameters of aromatase (q2 = 0.8429, r2 = 0.8874, r2pred = 0.8252) and steroidal sulfatase (q2 = 0.8877, r2 = 0.9402, r2pred = 0.9376) indicated the accuracy and reliability, and the good prediction power of the model. The external validation set further demonstrated its predictive capability. Furthermore, molecular docking, along with molecular dynamics at a time period of 100 ns, elucidated the stability of the docked complexes and found that Compound 109 emerged as the most promising dual inhibitor, exhibiting high binding affinities of -9.94 kcal/mol for Aromatase (AROM) and -9.41 kcal/mol for Steroid Sulfatase (STS). These values reflect a strong potential for dual enzyme inhibition. Discussion:: The structural features of triazole derivatives through QSAR modelling established a statistical correlation, establishing a relationship between functional groups and their biological activity. They are found to have dual inhibition efficiency in a target-based approach, accelerating for synthetic accessibility.

26 August 2024 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
AKA. Kathiraven
A. Kathiraven
SRSRIMATHI R
SRIMATHI R
KMKathiravan. M.K
Kathiravan. M.K
Current lifestyle of people prone way to oxidative stress and metabolic disturbances in the pathophysiology leading to disorders such as diabetes mellitus (DM). Type 2 DM is always of concern as it accounts for 90% of all the diabetic cases. The drugs used in treatment include a wide variety of classification such as sulfonylurea inhibitors, biguanides, thiazolidinediones, acarbose inhibitors etc and DPP-IV inhibitors are a newer treatment regimen recognised and approved by agencies like Food and Drug Administration (FDA) from the year 2005 in the treatment of T2DM. Dipeptidyl peptidase-4 (DPP-IV) enzyme primarily involved in the glucose homeostasis accounts for degradation of incretin hormones stimulating insulin secretion as a response to intake of food and maintaining blood sugar levels. Inhibitors of DPP-IV like Sitaglipitin, Vildagliptin, Aloglitpitin, Saxagliptin, Gemiglipitin, Teneglipitin etc prevents the degradation of hormones, thereby proving to be a method of treatment for T2DM. Cardiovascular complications including myocardial infarction, ischaemia, atherosclerosis associated in patients with T2DM are increasing on an alarming rate. Our review would focus on the analysing the effect of DPP-IV inhibitors in patients with cardiovascular defects and understand the mechanism involved.